Ron Cooper

Ron Cooper is a seasoned global CEO and board member currently leading enGene, a clinical-stage biotechnology company specializing in genetic medicines. With extensive experience in both biotech and big pharmaceutical sectors, they have successfully driven billion-dollar business transformations and facilitated significant drug approvals, including the first treatment for a rare pediatric liver disease. Ron has held key leadership roles, notably at Albireo Pharma, where they scaled the organization to a NASDAQ-listed entity, and at Bristol Myers Squibb, where they managed large international operations. Additionally, Ron serves on the boards of Generation Bio and C4 Therapeutics, demonstrating their commitment to advancing innovative therapies. They hold a Bachelor of Science degree in Chemistry and Business Administration from St. Francis Xavier University.